Scientist, Upstream Process Development at Acadia Pharmaceuticals

Minneapolis, Minnesota, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, MicrobiomeIndustries

Requirements

PhD (0-3 years), Master’s degree (3-5 years of experience), or Bachelor’s degree (5-8 years of experience) in chemical engineering, biochemistry, molecular biology, or a related field
Experience in pharmaceutical GXP regulated work is highly desired
Experience with fermentation equipment preferably microbial, including SIP capable instruments
Ability and desire to work independently as well as in a collaborative team-environment
Demonstrated technical writing skills required
Utilization of a continuous learning mindset to drive new technologies and solutions
Self-motivated individual able to drive projects forward with accountability for required timelines
Excellent oral and written communication skills
Organized and detail oriented

Responsibilities

Lead the execution of development and cGMP upstream manufacturing processes
Independently generate experimental designs using DoE to test hypotheses
Collect, analyze and interpret experimental results
Draw and present conclusions to team members in both written and visual formats
Troubleshoot and solve technical and equipment related challenges
Collaborate closely with other functions to enable effective and successful project execution
Organize, communicate, and present complex data to key stakeholders and senior management
Compile documentation (protocols, test methods, reports) to facilitate the tech transfer of early phase projects to internal and external stakeholders
Contribute towards lab and equipment maintenance and cleanliness

Skills

Upstream Process Development

cGMP

DoE

Experimental Design

Data Analysis

Troubleshooting

Tech Transfer

Microbiome Therapeutics

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free